Bio-Rad Laboratories, Inc. BIO-B
Set alert
As of Oct 27, 2:37 PM ET
- YTD
- +22.14%
- 1 year
- +25.19%
- Open
- 379.50
- Prev close
- 379.50
- Mkt cap
- 10.16B
- Vol
- 13
- Avg vol
- 9
- EPS
- 7.89
- P/E
- 48.10
- Div yield
- 0.00%
More statistics
- Low
- 379.50
- High
- 379.50
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 1.00
- Inst. own
- 0.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 365.78
- 200-d avg
- 310.70
- 1y target
- 0.00
2Y chart
Events in this range
- Jul 31, 2025Earnings: 2.61; estimate 1.75; surprise 49.14%
- Oct 29, 2025Earnings: 2.26; estimate 1.89; surprise 19.58%
- Feb 12, 2026Earnings: 2.51; estimate 2.69; surprise -6.69%
- Apr 30, 2026Earnings: 1.89; estimate 2.01; surprise -5.97%
- Aug 4, 2026Earnings: 2.62; estimate 1.78; surprise 47.19%
Signals (59)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| MACD: Sell Signal | Sep 3, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| RSI: Overbought | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 5 months ago |
| RSI: Oversold | May 5, 2026 | 5 months ago |
| SMA: Bullish | Apr 22, 2026 | 6 months ago |
| RSI: Overbought | Apr 22, 2026 | 6 months ago |
| SMA: Bullish | Apr 10, 2026 | 6 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| RSI: Oversold | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Dec 31, 2025 | 10 months ago |
| RSI: Overbought | Nov 14, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 31, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 19, 2025 | 1 year ago |
| RSI: Overbought | Sep 19, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Jul 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | May 13, 2025 | 1 year ago |
| RSI: Overbought | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 8, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 2, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 12, 2025 | 1 year ago |
| RSI: Oversold | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Jan 8, 2025 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
| RSI: Overbought | Nov 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 10.16B
- Enterprise value
- 9.90B
- Trailing P/E
- 48.10
- Forward P/E
- 0.00
- PEG ratio
- 4.23
- Price / sales
- 3.92
- Price / book
- 1.41
- EPS (TTM)
- 7.89
- Beta
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 8.59%
- Revenue (TTM)
- 2.59B
- Revenue growth
- -0.10%
- Free cash flow
- 283.19M
- Total cash
- 1.62B
- Total debt
- 1.37B
- Return on equity
- 3.11%
- Shares outstanding
- 5.06M
- Short % of float
- 0.00%
- 50-day average
- 365.78
- 200-day average
- 310.70
Analyst view
Consensus: none
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 2.23 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | 1.78 | 2.62 | +0.84 | +47.19% |
| Apr 30, 2026 | Mar 31, 2026 | 2.01 | 1.89 | -0.12 | -5.97% |
| Feb 12, 2026 | Dec 31, 2025 | 2.69 | 2.51 | -0.18 | -6.69% |
| Oct 29, 2025 | Sep 30, 2025 | 1.89 | 2.26 | +0.37 | +19.58% |
| Jul 31, 2025 | Jun 30, 2025 | 1.75 | 2.61 | +0.86 | +49.14% |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bio-rad.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BIO-B — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flow Traders U.S. LLC | 0.02% | 760 | 288.42K | Jun 29, 2026 |
| Morgan Stanley | 0.01% | 712 | 270.20K | Jun 29, 2026 |
| Whittier Trust Company | 0.00% | 160 | 60.72K | Jun 29, 2026 |
| UBS Group AG | 0.00% | 13 | 4.93K | Jun 29, 2026 |
| Wells Fargo & Company | 0.00% | 170 | 64.52K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gabelli Global Small & Mid Cap Value Trust | 0.00% | 150 | 56.92K | Sep 29, 2026 |